Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...

In this analysis, researchers aimed to quantify and bring attention to the time burden experienced by cancer patients enrolled in phase 2 clinical trials.

Researchers studied the affect of comorbidities and medication use on survival in patients with cutaneous squamous cell carcinoma using immune checkpoint inhibitors.

Nivolumab plus AVD is now FDA-approved for previously untreated Stage III or IV classical Hodgkin lymphoma in patients aged 12 years and older.

Patients testing positive for NPM1 MRD pre-alloHCT have significantly increased rates of relapse, reduced overall survival ...

Significantly more patients had no chemotherapy-induced thrombocytopenia-induced modification of chemo dose with romiplostim versus placebo ...

ASH convened a multidisciplinary panel to develop evidence-based guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, focusing on balancing treatment efficacy with ...

The 28th Wave of the Annenberg Survey of Attitudes on Public Health focused on the participants’ opinions on and awareness of various topics, including alcohol use.

Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

In this retrospective study, researchers explored the impact of telemedicine on recruitment and enrollment in a large phase 1 clinical trial program.

(HealthDay News) — Wastewater-based epidemiology is feasible as a community-level and population-level surveillance tool for colorectal cancer (CRC), according to a study published online March 17 in ...

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.